Advertisement
Advertisement
U.S. Markets close in 1 hr 20 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kazia Therapeutics Limited (KZIA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6900-0.1100 (-6.11%)
As of 02:40PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8000
Open1.7900
Bid1.6900 x 2200
Ask1.7100 x 800
Day's Range1.6800 - 1.8300
52 Week Range1.6300 - 12.2800
Volume307,631
Avg. Volume625,143
Market Cap23.383M
Beta (5Y Monthly)2.77
PE Ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.30
  • Benzinga

    Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases

    Kazia Therapeutics Limited (NASDAQ: KZIA) announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with radiotherapy for brain metastases. Interim data from the first stage of the study reports that all nine evaluable patients experienced a complete or partial response, representing an overall response rate (ORR) of 100%. A typical ORR associated with whole brain radiotherapy alone can commonly range from 20-45% in published studies. Also Read: Kazia Share

  • PR Newswire

    KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES

    Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase I clinical trial of paxalisib in combination with radiotherapy for the treatment of brain metastases, sponsored by Memorial Sloan Kettering Cancer Center in New York, NY.

  • Benzinga

    Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial

    Kazia Therapeutics Limited (NASDAQ: KZIA) said GBM AGILE, a pivotal study for paxalisib in newly diagnosed glioblastoma, did not meet pre-defined criteria for continuing to a second stage. Patients enrolled in the first stage of the paxalisib arm will continue on treatment as per protocol, and in follow-up, until completion of the final analysis, which Kazia anticipates receiving in 2H of 2023. Given that recruitment is complete, the study will not open to the paxalisib arm in Germany or China.

Advertisement
Advertisement